| Literature DB >> 32670613 |
João Rafael de Oliveira Dias1,2,3, Camila Campelo1,2, Eduardo Amorim Novais1,2, Gabriel Costa de Andrade1,2, Paula Marinho1,2, Yusláy Fernández Zamora1,2, Luciana Finamor Peixoto1,2, Maurício Maia1,2, Heloísa Nascimento1,2, Rubens Belfort1,2.
Abstract
BACKGROUND: Ocular toxoplasmosis is one of the most common causes of intraocular inflammation and posterior uveitis in immunocompetent patients. This paper aims to investigate swept-source optical coherence tomography angiography (SS-OCTA) findings in eyes with active toxoplasmic retinochoroiditis.Entities:
Keywords: Ocular toxoplasmosis; Optical coherence tomography angiography; Toxoplasmic retinochoroiditis
Year: 2020 PMID: 32670613 PMCID: PMC7346631 DOI: 10.1186/s40942-020-00231-2
Source DB: PubMed Journal: Int J Retina Vitreous ISSN: 2056-9920
Characteristics of patients with active ocular toxoplasmosis
| Patient no., age, gender, study eye | Symptom onseta | Lesion location (zone) | Lesion size (DD) | BCVA at baseline | BCVA at follow-up | IgM | IgG | Clinical findings |
|---|---|---|---|---|---|---|---|---|
| 1, 29 years, F, OD | 20 days | 1 | 2–3 | Hand motion | 20/125 | NR | R | ACC 3+, IRH, VC 2+, IRL |
| 2, 25 years, M, OS | 15 days | 2 | 1 | 20/20 | 20/20 | NR | R | ACC1+, RNV, VC1+ |
| 3, 22 years, M, OS | 1 day | 1 | < 1 | 20/60-2 | 20/25-1 | NR | R | ACC 3+, KP, VC 1+, IRL, CNVM |
| 4, 29 years, F, OD | 15 days | 1 | < 1 | 20/160 | 20/120-1 | R | R | ACC 3+, VC3+, IRL |
| 5, 20 years, M, OD | 4 days | 1 | < 1 | 20/25-2 | 20/20 | NR | R | VC 2+ |
| 6, 31 years, F, OS | 20 days | 1 | < 1 | 20/32 | 20/20 | NR | R | ACC 1+, VC 2+ |
| 7, 20 years, F, OD | 5 days | 1 | 1–2 | 20/125 | 20/40 | NR | R | ACC 3+, IRH, VC 1+ |
| 8, 15 years, F, OD | 10 days | 1 | 1–2 | 20/32-2 | 20/20 | NR | R | ACC 1+, VC 1+ |
| 9, 40 years, M, OD | 21 days | 1 | 2–3 | 20/500 | 20/334 | NR | R | ACC 3+, KP, VC 3+ |
| 10, 56 years, F, OS | 6 days | 1 | < 1 | Hand motion | 20/30 | NR | R | ACC 3+, KP, VC 2+ |
| 11, 41 years, F, OD | 15 days | 1 | 1–2 | 20/160 | 20/125 | R | R | ACC 2+, VC 2+ |
| 12, 39 years, F, OD | 5 days | 1 | 1–2 | 20/100 | 20/32 | NR | R | ACC 3+, VC1+ |
| 13, 28 years, M, OS | 6 days | 1 | 3 | 20/334 | 20/40 | NR | R | ACC 3+, KP, VC 1+ |
| 14, 59 years, F, OS | 15 days | 1 | > 6 DP | 20/125 | 20/40 | NR | R | ACC 3+, VC 2+ |
| 15, 32 years, M, OD | 5 days | 1 | 1–2 | CF 1 m | 20/100 | R | R | ACC 2+, VC 1+ |
DD disc diameter, BCVA best-corrected visual acuity, CF counting fingers, IgG toxoplasmosis immunoglobulin G, IgM toxoplasmosis immunoglobulin M, F female, M male, OD right eye, OS left eye, R reagent, NR non-reagent, ACC anterior chamber cells, VC vitreous cells, IRH intraretinal hemorrhage, RNV retinal neovascularization, KP keratic precipitates, CNVM choroidal neovascular membrane, IRL intraretinal loops
aTime interval between symptom onset and baseline evaluation
Fig. 1a Color fundus at the time of diagnosis. Vitritis and an active toxoplasmic lesion are visible in the papillomacular bundle. b Optical coherence tomography (OCT) B-scan with the total retina slabs. c OCT B-scan over the active lesion shows retinal hyperreflectivity (arrow) and a thickened choroid (asterisk) under the lesion. d A 9 × 9-mm field of view swept-source OCTA (SS-OCTA) image shows inferiorly located no OCTA decorrelation signal, suggestive of reduced blood flow. e Structural en face image. f Color fundus image 13 weeks after those in (a–e): inflammatory signs are absent, but an atrophic scar is visible. g OCT B-scan with the total retina slabs. h Retinal layers are unrecognizable at the lesion site (arrow) and choroidal thinning is seen (asterisk). i A 9 × 9-mm field of view on SS-OCTA shows increase in flow signal after treatment. The arrows indicate the vascular loops. j A structural en face image
Fig. 2a Color fundus at the time of diagnosis. An active toxoplasmic lesion is visible adjacent to the retinal choroidal pigmented scars. b An optical coherence tomography (OCT) B-scan with slabs extending from the vitreous to the inner nuclear layer. Thickened choroidal tissue is seen adjacent to the lesion site (asterisk). c An OCT B-scan with overlying color-coded flow in which red represents the retinal capillaries and pre-retinal neovascularization, and pink represents the choroid. d A 6 × 6-mm field of view on OCT angiography (OCTA) shows a neovascular seafan-like complex (arrow) and areas of no decorrelation signal. e A structural en face OCT shows a hyporeflective lesion suggestive of retinal neovascularization. f A color fundus image obtained 5 weeks after those in (a–e) shows that the area of retinitis has regressed following ocular toxoplasmosis treatment. g An OCT B-scan with slabs extending from the vitreous to the inner nuclear layer. h An OCT B-scan with overlying color-coded flow shows that the retinal neovascularization appears unchanged after the systemic anti-Toxoplasma treatment. i A 6 × 6-mm OCTA image shows unchanged retinal neovascularization (arrow). j A structural en face OCT image
Fig. 3a Color fundus 6 weeks after treatment. The pink and blue arrows indicate the B-scan positions in B and C. b An optical coherence tomography (OCT) B-scan with the outer retina slabs. Hyperreflective material is seen in the subretinal space (asterisk). c An OCT B-scan with overlying color-coded flow in which red represents the retinal capillaries, and pink represents the choroid and the choroidal neovascular membrane (CNVM). d A 3 × 3-mm field of view on a swept-source OCT angiography (SS-OCTA) image suggests the presence of a CNVM. e A structural en face OCT shows hyporeflective dots in the CNVM location. f Color fundus image 4 weeks after those in (a–e). g An OCT B-scan with the outer retina slabs. h An OCT B-scan with overlying color-coded flow. i A 3 × 3-mm OCTA image showing the CNVM. j A structural en face image
SS-OCT and SS-OCTA characteristics of patients with active ocular toxoplasmosis
| Patient no. | Thickened choroid below retinochoroiditis | Hyporeflective choroidal signal below retinochoroiditis | Reduced decorrelation signal adjacent to retinochoroiditis | Intraretinal abnormalities | Retinal neovascularization | Choroidal neovascular membrane | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | FU | Baseline | FU | Baseline | FU | Baseline | FU | Baseline | FU | Baseline | FU | |
| 1 | X | X | X | X | X | X | ||||||
| 2 | X | X | X | X | X | X | X | |||||
| 3 | X | X | X | N/A | X | N/A | X | N/A | N/A | X | ||
| 4 | X | X | X | |||||||||
| 5 | X | X | X | |||||||||
| 6 | X | X | X | X | X | |||||||
| 7 | X | X | X | X | X | |||||||
| 8 | X | X | X | |||||||||
| 9 | X | X | X | X | X | |||||||
| 10 | X | X | X | X | ||||||||
| 11 | X | X | X | X | ||||||||
| 12 | X | X | X | X | ||||||||
| 13 | X | X | X | X | X | |||||||
| 14 | X | X | X | X | ||||||||
| 15 | X | X | X | X | ||||||||
FU follow-up, N/A not available